Laura Sen-Martín

Laura Sen-Martín

Auto-generated profile, based on publicly available information

Laura Sen-Martín

Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
LSLaura Sen-Martín
Laura Sen-Martín
ÁFÁngel Fernández-Trasancos
Ángel Fernández-Trasancos
MLMiguel Á. López-Unzu
Miguel Á. López-Unzu
DPDivya Pathak
Divya Pathak
AFAlessia Ferrarini
Alessia Ferrarini
JAJorge Alegre-Cebollada
Jorge Alegre-Cebollada
Myosin inhibitor mavacamten is the only targeted treatment available for hypertrophic cardiomyopathy (HCM), a disease caused by hundreds of genetic variants that affect mainly sarcomeric myosin and its negative regulator cardiac myosin-binding protein C (cMyBP-C, encoded by MYBPC3 ). Here, we have examined whether the reported limited efficacy of mavacamten in a fraction of HCM patients can result from dissimilar HCM pathomechanisms triggered by different genetic variants, a scenario particularly relevant for MYBPC3 -associated HCM. To this aim, we have generated knock-in mice including missense pathogenic variant cMyBP-C p.R502W, which, different from patients who carry truncations in the protein, develop progressive pathogenic myocardial remodeling in the absence of alterations of cMyBP-C levels and localization. Mechanistically, we find that mutation R502W reduces the binding affinity of cMyBP-C for myosin without inducing a shift towards more active myosin conformations as observed when cMyBP-C levels are reduced. Despite these diverging molecular alterations, we show that mavacamten blunts myocardial remodeling both in R502W and cMyBP-C-deficient, knock-out hearts. These beneficial effects are accompanied by improved tolerance to exercise only in R502W animals. Hence, our results indicate that myosin inhibition is effective to treat HCM caused by both truncating and missense variants in MYBPC3 regardless of the primary pathomechanisms they elicit.

7 July 2026 in Nature Cardiovascular Research
Verified
Journal Article
Closed access
PDF file
LSLaura Sen-Martín
Laura Sen-Martín
ÁFÁngel Fernández-Trasancos
Ángel Fernández-Trasancos
MLMiguel Á. López-Unzu
Miguel Á. López-Unzu
ABAgata Bak
Agata Bak
MZMagdalena Zafra-Castellano
Magdalena Zafra-Castellano
JAJorge Alegre-Cebollada
Jorge Alegre-Cebollada